Coherus BioSciences to Participate at Upcoming September Investor Conferences
Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Coherus BioSciences, Inc. announced participation in investor conferences.
Positive
- None.
Negative
- None.
REDWOOD CITY, Calif., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor conferences:
- Citi's 2023 18th Annual BioPharma Conference in Boston on Wednesday, September 6, 2023, including participation in an I-O Panel Discussion at 3:30 p.m. EDT.
- 2023 Wells Fargo Healthcare Conference in Boston on Thursday, September 7, 2023 for 1x1 meetings only.
- H.C. Wainwright 25th Annual Global Investment Conference in New York on September 12-13, 2023 for a fireside chat-format presentation on Tuesday, September 12, 2023 at 1:30 pm EDT.
A live audio webcast and an archive of the presentations from the Citi and HCW conferences will be available on the investors’ page of the Coherus website at http://investors.coherus.com.
Coherus Contact Information:
Marek Ciszewski, SVP Investor Relations
IR@coherus.com
Coherus BioSciences, Inc.
NASDAQ:CHRS
CHRS Rankings
CHRS Latest News
Apr 24, 2024
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 8, 2024
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
CHRS Stock Data
246.29M
103.90M
1.35%
77.99%
20.8%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
United States of America
REDWOOD CITY
About CHRS
coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp